- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| So | Celltrion's Remsima stays Korea's top-produced drug | 2 | Korea Herald | ||
| Fr | Celltrion's Abtozma Gains Major U.S. PBM Listing | 2 | BusinessKorea | ||
| CELLTRION Aktie jetzt für 0€ handeln | |||||
| Fr | Celltrion's Avtozma biosimilar added to U.S. preferred drug list | 2 | Yonhap News | ||
| 09.12. | Celltrion Enters SC Formulation Market | 1 | BusinessKorea | ||
| 04.12. | Celltrion ADC candidate gets FDA fast track designation | 4 | Korea Herald | ||
| 03.12. | FDA Clears New Prefilled Syringe Of Celltrion's OMLYCLO, Interchangeable Biosimilar To XOLAIR | 343 | AFX News | SEOUL (dpa-AFX) - Celltrion Inc. announced that the U.S. Food and Drug Administration (FDA) has approved a new presentation of OMLYCLO (omalizumab-igec)-the first and only biosimilar designated... ► Artikel lesen | |
| 03.12. | FDA approves new dosing option for Celltrion's omalizumab biosimilar | 13 | Investing.com | ||
| 03.12. | Celltrion announces U.S. FDA approval of 300mg strength of OMLYCLO (omalizumab-igec), the first and only FDA-approved interchangeable biosimilar to XOLAIR | 85 | PR Newswire | FDA approval of OMLYCLO® (omalizumab-igec) 300 mg/2 mL solution in a single-dose prefilled syringe for subcutaneous injection expands dosing flexibility and supports... ► Artikel lesen | |
| 02.12. | Celltrion, Galux partner on multispecific antibody drugs | 1 | Korea Herald | ||
| 01.12. | Celltrion biosimilar added to 2 preferred drugs lists in U.S. | 3 | Yonhap News | ||
| 28.11. | Celltrion secures Health Canada go-ahead for Eylea biosimilar | 1 | Pharmaceutical Technology | ||
| 25.11. | Export-Import Bank Provides 350 Billion Won Support for Celltrion's U.S. Production Facility M&A | 3 | BusinessKorea | ||
| 25.11. | Celltrion, Inc.: Celltrion erhält Zulassungserweiterung der Europäischen Kommission für Omlyclo 300 mg | 270 | Business Wire | Omlyclo (Omalizumab) ist das erste und einzige in Europa zugelassene Omalizumab-Biosimilar Omlyclo 300 mg 2 ml in der Darreichungsform einer vorgefüllten Spritze (PFS) ist jetzt in der... ► Artikel lesen | |
| 25.11. | Celltrion Completes "Omliklo' Launch Across Major European Markets | 2 | BusinessKorea | ||
| 25.11. | Celltrion launches biosimilar Omlyclo in major European countries | 2 | Yonhap News | ||
| 19.11. | Celltrion to widen US manufacturing reach with $478M investment at former Lilly plant | 4 | FiercePharma | ||
| 19.11. | Celltrion still thinking bigger than biosimilars with option for $350M antibody deal | 1 | FierceBiotech | ||
| 19.11. | Celltrion Plans to Develop Oral Obesity Drug With Weight Reduction Rate of Over 25% | 5 | BusinessKorea | ||
| 19.11. | Celltrion to invest 4 trillion won to expand domestic facilities | 3 | Korea Joongang Daily | ||
| 19.11. | Celltrion ramps up U.S. plant upgrade to preempt tariff risks | 1 | Korea Herald |
1 2 3 4 5 Weiter >>
124 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| IMMUNOME | 22,640 | 0,00 % | Why Immunome Stock Surged Today | ||
| APOGEE THERAPEUTICS | 76,81 | -0,35 % | Apogee Therapeutics stock initiated with Buy rating at Deutsche Bank | ||
| RECURSION PHARMACEUTICALS | 4,200 | 0,00 % | Why Recursion Pharamaceuticals Topped the Market Today | ||
| ADMA BIOLOGICS | 19,730 | -0,25 % | ADMA Biologics, Inc.: ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update | 2Q 2025 Total Revenue of $122.0 Million, a 14% YoY Increase, and a 29% YoY Increase Excluding a Prior Year Non-Recurring Item 2Q 2025 GAAP Net Income of $34.2 Million, a 7% YoY Increase 2Q 2025 Adjusted... ► Artikel lesen | |
| QIAGEN | 38,335 | 0,00 % | JEFFERIES stuft QIAGEN NV auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Qiagen mit einem Kursziel von 57 US-Dollar auf "Buy" belassen. Die Profitabilität dürfte 2026 zumindest stabil bleiben... ► Artikel lesen | |
| DISC MEDICINE | 92,00 | +0,16 % | H.C. Wainwright reiterates Buy rating on Disc Medicine stock | ||
| VERA THERAPEUTICS | 49,170 | 0,00 % | Vera Therapeutics, Inc. - 8-K, Current Report | ||
| ARTIVA BIOTHERAPEUTICS | 6,300 | 0,00 % | Artiva Biotherapeutics, Inc. - 8-K, Current Report | ||
| NURIX THERAPEUTICS | 19,010 | -0,31 % | Cathie Wood's ARK sells Iridium stock, buys Nurix on Wednesday | ||
| RADIOPHARM THERANOSTICS | 10,630 | 0,00 % | Radiopharm (RADX) Sees Slight Pessimism From Analysts | ||
| KYVERNA THERAPEUTICS | 10,810 | 0,00 % | Kyverna Therapeutics, Inc.: Kyverna Therapeutics Announces Positive Topline Data from Registrational KYSA-8 Trial of Miv-cel (KYV-101) in Stiff Person Syndrome | Landmark results could pave the way for miv-cel to become the first FDA-approved CAR T-cell therapy for autoimmune disease; Company on track to submit BLA for stiff person syndrome in 1H 2026 Miv-cel... ► Artikel lesen | |
| OLEMA PHARMACEUTICALS | 35,840 | 0,00 % | Olema Pharmaceuticals stock price target raised to $45 at H.C. Wainwright | ||
| PRAXIS PRECISION MEDICINES | 276,42 | +2,83 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Plans to File an NDA for Relutrigine in SCN2A and SCN8A Developmental and Epileptic Encephalopathies in Early 2026 | BOSTON, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies... ► Artikel lesen | |
| BIONTECH | 80,30 | +0,63 % | BioNTech-Aktie: Die Hoffnung ist zurück | Die Mainzer stärken ihre eigene Position im Markt, neue Daten dürften Aufwärtsdruck liefern. Mit der Übernahme von Curevac, die nach Erreichen der Mindestannahmeschwelle Ende letzter Woche noch in diesem... ► Artikel lesen | |
| LENZ THERAPEUTICS | 17,080 | -5,84 % | LENZ Therapeutics, Inc. - 8-K, Current Report |
CELLTRION INC gehört der Branche Biotechnologie an.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CELLTRION INC finden Sie auf Wallstreet Online.